Lates News

Every AI fast news, Southwest Securities released research report on April 3, giving a "buy" rating to Reperon Biological (300119.SZ). The main reasons for the rating include: 1) optimized product structure, high gross profit business and emerging market performance; 2) continuous increase in research and development investment, fine management releasing profits; 3) 11% / 33% year-on-year revenue / net profit attributable to parent growth by 2025, achieving high-quality performance growth. (Daily Economic News)